Literature DB >> 11535213

Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants.

I Sivin1, L Wan, S Ranta, F Alvarez, V Brache, D R Mishell, P Darney, A Biswas, S Diaz, O Kiriwat, M P Anant, C Klaisle, M Pavez, J Schechter.   

Abstract

Serum levonorgestrel concentrations were assayed in a multicenter, 7-year study of 199 users of Jadelle rod implants. We examined drug levels, patterns of changes, factors affecting drug levels, and concentrations at which pregnancies occurred. Mean levonorgestrel concentrations declined from 435 pg/mL at 1 month of use to 64% of that value (280 pg/mL) at the end of 3 years. Between the end of the third and fifth years neither mean nor median serum levels varied markedly. At 5 years the mean concentration was again 64% of the first month's mean. Declining levels were observed thereafter through the end of 7 years when the mean, 224 pg/mL, was 52% of the 1-month value. Last measured drug concentrations of women who became pregnant during Jadelle use had mean and median values of 152 and 144 pg/mL, respectively, and a maximum value of 180 pg/mL. Analyses indicated ponderal index, body weight, duration of use, and a single clinical center were the most important variables affecting measured levonorgestrel levels. Approximately one-third of assays in the sixth and seventh years were found to be below 180 pg/mL, suggesting that Jadelle levonorgestrel implants would not maintain sufficiently high levels of effectiveness against pregnancy after 5 years and that heavier women would then be at greater risk of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535213     DOI: 10.1016/s0010-7824(01)00226-8

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  24 in total

1.  Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth R Mayeda; Malcolm C Pike; Frank Z Stanczyk
Journal:  Contraception       Date:  2010-02-20       Impact factor: 3.375

2.  Carbamazepine coadministration with an oral contraceptive: effects on steroid pharmacokinetics, ovulation, and bleeding.

Authors:  Anne R Davis; Carolyn L Westhoff; Frank Z Stanczyk
Journal:  Epilepsia       Date:  2011-01-04       Impact factor: 5.864

3.  Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma.

Authors:  Lauren R Cirrincione; Sujan Dilly Penchala; Kimberly K Scarsi; Anthony T Podany; Lee C Winchester; David J Back; Saye H Khoo; Courtney V Fletcher; Marco Siccardi; Laura J Else
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-12       Impact factor: 3.205

4.  A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.

Authors:  Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson
Journal:  Contemp Clin Trials       Date:  2016-11-09       Impact factor: 2.226

5.  A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.

Authors:  Rena C Patel; Randy M Stalter; Katherine K Thomas; Bani Tamraz; Steven W Blue; David W Erikson; Christina J Kim; Edward J Kelly; Kavita Nanda; Athena P Kourtis; Jairam R Lingappa; Nelly Mugo; Jared M Baeten; Kimberly K Scarsi
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

6.  Pharmacokinetics of Hormonal Contraception in Individuals with Obesity: a Review.

Authors:  Shaalini Ramanadhan; William J Jusko; Alison Edelman
Journal:  Curr Obstet Gynecol Rep       Date:  2020-05-04

7.  Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.

Authors:  Marcia A Ciccone; Stephanie A Whitman; Charlotte L Conturie; Niquelle Brown; Christina E Dancz; Begum Özel; Koji Matsuo
Journal:  Arch Gynecol Obstet       Date:  2019-01-31       Impact factor: 2.344

Review 8.  Clarification of contraceptive drug pharmacokinetics in obesity.

Authors:  William J Jusko
Journal:  Contraception       Date:  2016-08-16       Impact factor: 3.375

Review 9.  Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants.

Authors:  Irving Sivin
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Authors:  M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.